|
Market Closed -
Nasdaq
21:00:00 28/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 124.37 USD | -2.64% |
|
-2.69% | +25.92% |
| 08-28 | US FDA approves Takeda, Protagonist's drug for rare blood cancer | RE |
| 08-28 | Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil | MT |
Chart: Technical Analysis
Stock exchange
Nasdaq
INCY 124.37 $
-2.64%
151M
$
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
Nasdaq
| INCY | 124.37USD | -2.64% | 151M $ | |
CBOE
| INCY | 124.35USD | -2.60% | 4.85M $ | |
|
Mexican S.E.
| INCY * | 2,122.50MXN | +4.25% | 1.18M $ | |
|
Boerse Muenchen
| ICY | 107.15EUR | -2.19% | 30.64K € | |
|
Tradegate
| ICY | 107.35EUR | -2.10% | 9.55K € | |
|
Xetra
| ICY | 108.25EUR | -1.10% | 1.52K € | |
|
Berne S.E.
| ICY | 103.57CHF | +10.15% | 932.11 CHF | |
|
Deutsche Boerse AG
| ICY | 108.55EUR | -0.82% | 0 € | |
|
Börse Stuttgart
| ICY | 106.70EUR | -2.65% | 0 € | |
|
Borsa Italiana
| 1INCY | 109.65EUR | -0.59% | 0 € | |
Sao Paulo
| I1NC34 | 328.02BRL | -0.20% | 2.3K R$ |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bullish | Bullish |
| Resistance | 129.93 | 129.93 | 127.81 |
| Spread/Res. | -4.28% | -4.28% | -2.69% |
| Spread/Supp. | +7.54% | +14.60% | +21.11% |
| Support | 115.65 | 108.53 | 102.69 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- INCY Stock
- Charts Incyte Corporation
Select your edition
All financial news and data tailored to specific country editions
